Juan Luis B. P.
- Country
- Spain
- Department
- Internal Medicine
Research Overview
- Efficacy and Safety of LY3540378 in Adults with Worsening Chronic Heart Failure with Preserved Ejection Fraction: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Omecamtiv Mecarbil in Patients with Heart Failure and Severely Reduced Ejection Fraction: A Randomized, Double-Blind, Placebo-Controlled Trial
- CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).
Data & Insights
Has run more than one trial at 33 of 169 partner sites.
Specializations
Heart Failure
Juan Luis Bonilla Palomas is involved in clinical research focused on heart failure across symptomatic and worsening chronic presentations, with attention to both functional impairment and cardiovascular outcomes in patients managed within internal medicine and a dedicated heart failure unit.
- Chronic heart failure
- Symptomatic heart failure
- Cardiovascular morbidity
- Cardiovascular mortality
His trial activity reflects a strong therapeutic interest in treatments aimed at reducing heart failure-related complications and improving clinical stability in patients treated at Hospital San Juan de la Cruz.
Heart Failure With Reduced Ejection Fraction
His research includes heart failure with reduced ejection fraction, with emphasis on patients with severely reduced ventricular function and persistent disease burden despite standard medical care.
- Severely reduced ejection fraction
- Guideline-directed medical therapy
- HF outcomes
- Chronic systolic dysfunction
This area of interest places attention on therapies designed to improve prognosis in advanced HFrEF and to address ongoing risk in patients with limited cardiac reserve.
Heart Failure With Preserved Ejection Fraction
He is also engaged in research on heart failure with preserved ejection fraction, particularly in worsening chronic disease where atrial and structural abnormalities contribute to clinical deterioration.
- Atrial myopathy
- Worsening chronic HFpEF
- Cardiac remodeling
- Functional limitation
His clinical focus in this domain is centered on therapeutic strategies for HFpEF that target the underlying cardiac substrate and symptom burden.
Transthyretin Amyloid Cardiomyopathy
Another key area of interest is variant or wild-type transthyretin amyloid cardiomyopathy, a condition marked by infiltrative cardiac disease and progressive heart failure symptoms.
- ATTRwt cardiomyopathy
- ATTRv cardiomyopathy
- Cardiac amyloidosis
- Progressive heart failure
His involvement in this field highlights a therapeutic focus on innovative approaches for ATTR amyloidosis with cardiovascular involvement, especially in patients at risk of worsening morbidity and mortality.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.